New Enhertu approval a milestone in lung cancer
AstraZeneca (LSE: AZN) and Daiichi Sankyo’s (TYO: 4568) drug Enhertu (trastuzumab deruxtecan) has become the first HER2-directed therapy to be approved in the USA for patients with previously-treated HER2-mutant metastatic non-small cell lung cancer.
The approval was based on DESTINY-Lung02 results, which showed that Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease.
"The approval of the first HER2-directed treatment option validates HER2 as an actionable target in lung cancer"HER2-targeting drugs have been on the market since the 1990s, with Roche’s Herceptin (trastuzumab) leading the way and Perjeta (pertuzumab) and Kadcyla (trastuzumab emtansine) following on afterwards. But they have largely been given to breast cancer patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze